| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Conroy Kevin T | President and CEO, Director | C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON | /s/ Kevin T. Conroy by Mark Busch, attorney-in- fact | 30 Dec 2025 | 0001306119 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EXAS | Common Stock | Award | $0 | +244,931 | +29% | $0.000000 | 1,101,519 | 23 Dec 2025 | Direct | F1 |
| transaction | EXAS | Common Stock | Tax liability | $11,721,315 | -115,118 | -10% | $101.82 | 986,401 | 23 Dec 2025 | Direct | F2 |
| transaction | EXAS | Common Stock | Award | $0 | +138,326 | +14% | $0.000000 | 1,124,727 | 23 Dec 2025 | Direct | F3 |
| transaction | EXAS | Common Stock | Tax liability | $6,619,725 | -65,014 | -5.8% | $101.82 | 1,059,713 | 23 Dec 2025 | Direct | F2 |
| transaction | EXAS | Common Stock | Award | $0 | +330,674 | $0.000000 | 155,417 | 23 Dec 2025 | Direct | F4 | |
| transaction | EXAS | Common Stock | Tax liability | $15,824,559 | -155,417 | -11% | $101.82 | 1,234,970 | 23 Dec 2025 | Direct | F2, F5 |
| holding | EXAS | Common Stock | 28,806 | 23 Dec 2025 | Held in 401(k) Plan | ||||||
| holding | EXAS | Common Stock | 46,538 | 23 Dec 2025 | Held in Grantor Retained Annuity Trust | ||||||
| holding | EXAS | Common Stock | 86,750 | 23 Dec 2025 | Held in Grantor Retained Annuity Trust | ||||||
| holding | EXAS | Common Stock | 117,427 | 23 Dec 2025 | Held in Grantor Retained Annuity Trust |
| Id | Content |
|---|---|
| F1 | Represents performance-based restricted share units granted to the reporting person on February 24, 2023 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2025. The vesting of the portion reflected herein was accelerated in order to mitigate the potential impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, on the Issuer and certain of its employees in connection with the pending transactions contemplated by the Agreement and Plan of Merger, dated November 19, 2025, by and among the Issuer, Abbott Laboratories, and Badger Merger Sub I, Inc. (the "Section 280G Mitigation"). |
| F2 | Represents shares of Common Stock retained by the Issuer for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance based restricted stock units. |
| F3 | Represents performance-based restricted share units granted to the reporting person on February 26, 2024 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2026. The vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. |
| F4 | Represents performance-based restricted share units granted to the reporting person on February 24, 2025 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2027. The vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. |
| F5 | In addition to the shares of Common Stock reported on this Form 4, which total 1,514,491 shares, Mr. Conroy also holds, in the aggregate, an additional 663,578 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock |